Â鶹Éç

They are a topical drug delivery company developing a pipeline of targeted treatments for conditions that currently lack approved therapy options. AFYX’s Rivelin^® patch attaches to mucosal surfaces to ensure therapeutic delivery to mucosal tissue. Rivelin-CLO, their lead drug candidate/therapeutic finished a successful phase IIb trial against oral lichen planus in 2020. They are also developing treatments for various indications in mucosal diseases which have significant unmet need such as Vulvar Lichen Sclerosus.